Archive - de novo by Seed Investments team (@Novo Holdings)

November 2023

Neuromuscular disease treatments moving in the right direction

Skeletal muscles are essential for human movement and account for about 40% of the body mass.

Nov 15, 2023 •

Seeds' team (Novo Holdings)

September 2023

Atrial Fibrillation on the Rise: Challenges and Opportunities for Safer Treatment Options

Atrial Fibrillation (AF) is the most common type of cardiac arrhythmia, affecting an estimated 4.5 million people in Europe alone.

Sep 28, 2023 •

Seeds' team (Novo Holdings)

May 2023

Hemab’s Blood Clotting Therapies at the heart of human resilience

While patients with common bleeding and thrombotic disorders have had access to preventative treatments for more than a half-century, no such measures…

May 23, 2023 •

Seeds' team (Novo Holdings)

February 2023

International Day of Women and Girls in Science — interview with Asgard Therapeutics’ CEO and…

International Day of Women and Girls in Science — interview with Asgard Therapeutics’ CEO and co-founder

Feb 11, 2023 •

Seeds' team (Novo Holdings)

March 2022

Entrepreneurs in and out of residence — a dual perspective on the role of EiRs in venture creation

Entrepreneurs in and out of residence — a dual perspective on the role of EiRs in venture creation

Mar 31, 2022 •

Seeds' team (Novo Holdings)

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts